Skip to main content
Erschienen in: Skeletal Radiology 4/2012

01.04.2012 | Scientific Article

Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response

verfasst von: Yoshiko Yamashita, Takatoshi Aoki, Takeshi Hanagiri, Chiharu Yoshii, Hiroshi Mukae, Hidetaka Uramoto, Yukunori Korogi

Erschienen in: Skeletal Radiology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess the frequency of osteosclerotic changes on CT that appeared after treatment with gefitinib in patients with lung adenocarcinoma and the relationship between the osteosclerotic changes and the response to the therapy.

Materials and methods

Our study included 41 patients with lung adenocarcinoma who underwent chest CT both before (CTpre) and after (CTpost) starting treatment with gefitinib. The presence or absence of bone metastases was assessed on the CTpre, and the interval bony change after the therapy was classified as lytic, sclerotic, or no changes on the CTpost. The relationship between treatment results of primary lung cancer and interval bony changes was evaluated.

Results

Osteosclerotic lesions were identified in 11 patients (27%) on CTpost; in 6 of 11 patients osteosclerotic lesions newly appeared where the CTpre showed no bone metastasis before the gefitinib therapy. There were significant differences in the therapeutic response of the primary cancers (P < 0.001) and in the survival rate (P < 0.01) in patients with osteosclerotic changes versus those without osteosclerotic changes.

Conclusion

Osteosclerotic changes on CT, observed after gefitinib treatment in patients with lung adenocarcinomas, may be an indicator of a good therapeutic response.
Literatur
1.
Zurück zum Zitat Pao W, Zakowski M, Cordon-Cardo C, et al. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. Proc Am Soc Clin Oncol 2004; 23: 623 s (abstract). Pao W, Zakowski M, Cordon-Cardo C, et al. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. Proc Am Soc Clin Oncol 2004; 23: 623 s (abstract).
2.
Zurück zum Zitat Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237–46.PubMedCrossRef Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237–46.PubMedCrossRef
3.
Zurück zum Zitat Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005;12:471–82.PubMedCrossRef Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005;12:471–82.PubMedCrossRef
4.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef
6.
Zurück zum Zitat Zampa G, Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, et al. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer. 2008;60:452–4.PubMedCrossRef Zampa G, Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, et al. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer. 2008;60:452–4.PubMedCrossRef
7.
Zurück zum Zitat Satoh H, Ishikawa H, Ohara G, Kikuchi N, Sekizawa K. Prolonged response to gefitinib in bone metastasis. Med Oncol. 2009;26:102–2. Satoh H, Ishikawa H, Ohara G, Kikuchi N, Sekizawa K. Prolonged response to gefitinib in bone metastasis. Med Oncol. 2009;26:102–2.
8.
Zurück zum Zitat Okano Y, Nishio M. Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium. 2008;18:527–33.PubMed Okano Y, Nishio M. Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium. 2008;18:527–33.PubMed
9.
Zurück zum Zitat Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastasis in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552–9.PubMed Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastasis in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552–9.PubMed
10.
Zurück zum Zitat Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastasis in patients with breast cancer. A dose-seeking study. Cancer. 1994;74:2949–55.PubMedCrossRef Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastasis in patients with breast cancer. A dose-seeking study. Cancer. 1994;74:2949–55.PubMedCrossRef
11.
Zurück zum Zitat Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785–91.PubMedCrossRef Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785–91.PubMedCrossRef
12.
Zurück zum Zitat Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2001;19:3562–71.PubMed Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2001;19:3562–71.PubMed
13.
Zurück zum Zitat Normanno N, Gullick WJ. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer. 2006;13:3–6.PubMedCrossRef Normanno N, Gullick WJ. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer. 2006;13:3–6.PubMedCrossRef
14.
Zurück zum Zitat Dawar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334–7.CrossRef Dawar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334–7.CrossRef
15.
Zurück zum Zitat Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006–2013.PubMedCrossRef Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006–2013.PubMedCrossRef
16.
Zurück zum Zitat Chao HS, Chang CP, Chiu CH, et al. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009;34:346–9.PubMedCrossRef Chao HS, Chang CP, Chiu CH, et al. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009;34:346–9.PubMedCrossRef
17.
Zurück zum Zitat Yamaguchi T. Intertrabecular vertebral metastases: metastases only detectable on MR imaging. Semin Musculoskelet Radiol. 2001;5:171–5.PubMedCrossRef Yamaguchi T. Intertrabecular vertebral metastases: metastases only detectable on MR imaging. Semin Musculoskelet Radiol. 2001;5:171–5.PubMedCrossRef
Metadaten
Titel
Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response
verfasst von
Yoshiko Yamashita
Takatoshi Aoki
Takeshi Hanagiri
Chiharu Yoshii
Hiroshi Mukae
Hidetaka Uramoto
Yukunori Korogi
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Skeletal Radiology / Ausgabe 4/2012
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-011-1253-9

Weitere Artikel der Ausgabe 4/2012

Skeletal Radiology 4/2012 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.